Report cover image

Global Adult and Pediatric Vaccines Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 194 Pages
SKU # APRC20561924

Description

Summary

According to APO Research, The global Adult and Pediatric Vaccines market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Adult and Pediatric Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Adult and Pediatric Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Adult and Pediatric Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Adult and Pediatric Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Adult and Pediatric Vaccines include Sanofi, Johnson and Johnson, Novartis, Merck, Pfizer, GlaxoSmithKline, Sinovac Biotech, AstraZeneca and Takeda Pharmaceutical, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Adult and Pediatric Vaccines, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Adult and Pediatric Vaccines, also provides the revenue of main regions and countries. Of the upcoming market potential for Adult and Pediatric Vaccines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Adult and Pediatric Vaccines revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Adult and Pediatric Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Adult and Pediatric Vaccines revenue, projected growth trends, production technology, application and end-user industry.

Adult and Pediatric Vaccines Segment by Company

Sanofi
Johnson and Johnson
Novartis
Merck
Pfizer
GlaxoSmithKline
Sinovac Biotech
AstraZeneca
Takeda Pharmaceutical
LG Life Sciences
Bavarian Nordic
Adult and Pediatric Vaccines Segment by Type

Adult Vaccines
Pediatric Vaccines
Adult and Pediatric Vaccines Segment by Application

Hospitals
Medical Care Centers
Others
Adult and Pediatric Vaccines Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Adult and Pediatric Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Adult and Pediatric Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Adult and Pediatric Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Adult and Pediatric Vaccines in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Adult and Pediatric Vaccines company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Adult and Pediatric Vaccines revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

194 Pages
1 Market Overview
1.1 Product Definition
1.2 Adult and Pediatric Vaccines Market by Type
1.2.1 Global Adult and Pediatric Vaccines Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Adult Vaccines
1.2.3 Pediatric Vaccines
1.3 Adult and Pediatric Vaccines Market by Application
1.3.1 Global Adult and Pediatric Vaccines Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Medical Care Centers
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Adult and Pediatric Vaccines Market Dynamics
2.1 Adult and Pediatric Vaccines Industry Trends
2.2 Adult and Pediatric Vaccines Industry Drivers
2.3 Adult and Pediatric Vaccines Industry Opportunities and Challenges
2.4 Adult and Pediatric Vaccines Industry Restraints
3 Global Growth Perspective
3.1 Global Adult and Pediatric Vaccines Market Perspective (2020-2031)
3.2 Global Adult and Pediatric Vaccines Growth Trends by Region
3.2.1 Global Adult and Pediatric Vaccines Market Size by Region: 2020 VS 2024 VS 2031
3.2.2 Global Adult and Pediatric Vaccines Market Size by Region (2020-2025)
3.2.3 Global Adult and Pediatric Vaccines Market Size by Region (2026-2031)
4 Competitive Landscape by Players
4.1 Global Adult and Pediatric Vaccines Revenue by Players
4.1.1 Global Adult and Pediatric Vaccines Revenue by Players (2020-2025)
4.1.2 Global Adult and Pediatric Vaccines Revenue Market Share by Players (2020-2025)
4.1.3 Global Adult and Pediatric Vaccines Players Revenue Share Top 10 and Top 5 in 2024
4.2 Global Adult and Pediatric Vaccines Key Players Ranking, 2023 VS 2024 VS 2025
4.3 Global Adult and Pediatric Vaccines Key Players Headquarters & Area Served
4.4 Global Adult and Pediatric Vaccines Players, Product Type & Application
4.5 Global Adult and Pediatric Vaccines Players Establishment Date
4.6 Market Competitive Analysis
4.6.1 Global Adult and Pediatric Vaccines Market CR5 and HHI
4.6.3 2024 Adult and Pediatric Vaccines Tier 1, Tier 2, and Tier 3
5 Adult and Pediatric Vaccines Market Size by Type
5.1 Global Adult and Pediatric Vaccines Revenue by Type (2020 VS 2024 VS 2031)
5.2 Global Adult and Pediatric Vaccines Revenue by Type (2020-2031)
5.3 Global Adult and Pediatric Vaccines Revenue Market Share by Type (2020-2031)
6 Adult and Pediatric Vaccines Market Size by Application
6.1 Global Adult and Pediatric Vaccines Revenue by Application (2020 VS 2024 VS 2031)
6.2 Global Adult and Pediatric Vaccines Revenue by Application (2020-2031)
6.3 Global Adult and Pediatric Vaccines Revenue Market Share by Application (2020-2031)
7 Company Profiles
7.1 Sanofi
7.1.1 Sanofi Comapny Information
7.1.2 Sanofi Business Overview
7.1.3 Sanofi Adult and Pediatric Vaccines Revenue and Gross Margin (2020-2025)
7.1.4 Sanofi Adult and Pediatric Vaccines Product Portfolio
7.1.5 Sanofi Recent Developments
7.2 Johnson and Johnson
7.2.1 Johnson and Johnson Comapny Information
7.2.2 Johnson and Johnson Business Overview
7.2.3 Johnson and Johnson Adult and Pediatric Vaccines Revenue and Gross Margin (2020-2025)
7.2.4 Johnson and Johnson Adult and Pediatric Vaccines Product Portfolio
7.2.5 Johnson and Johnson Recent Developments
7.3 Novartis
7.3.1 Novartis Comapny Information
7.3.2 Novartis Business Overview
7.3.3 Novartis Adult and Pediatric Vaccines Revenue and Gross Margin (2020-2025)
7.3.4 Novartis Adult and Pediatric Vaccines Product Portfolio
7.3.5 Novartis Recent Developments
7.4 Merck
7.4.1 Merck Comapny Information
7.4.2 Merck Business Overview
7.4.3 Merck Adult and Pediatric Vaccines Revenue and Gross Margin (2020-2025)
7.4.4 Merck Adult and Pediatric Vaccines Product Portfolio
7.4.5 Merck Recent Developments
7.5 Pfizer
7.5.1 Pfizer Comapny Information
7.5.2 Pfizer Business Overview
7.5.3 Pfizer Adult and Pediatric Vaccines Revenue and Gross Margin (2020-2025)
7.5.4 Pfizer Adult and Pediatric Vaccines Product Portfolio
7.5.5 Pfizer Recent Developments
7.6 GlaxoSmithKline
7.6.1 GlaxoSmithKline Comapny Information
7.6.2 GlaxoSmithKline Business Overview
7.6.3 GlaxoSmithKline Adult and Pediatric Vaccines Revenue and Gross Margin (2020-2025)
7.6.4 GlaxoSmithKline Adult and Pediatric Vaccines Product Portfolio
7.6.5 GlaxoSmithKline Recent Developments
7.7 Sinovac Biotech
7.7.1 Sinovac Biotech Comapny Information
7.7.2 Sinovac Biotech Business Overview
7.7.3 Sinovac Biotech Adult and Pediatric Vaccines Revenue and Gross Margin (2020-2025)
7.7.4 Sinovac Biotech Adult and Pediatric Vaccines Product Portfolio
7.7.5 Sinovac Biotech Recent Developments
7.8 AstraZeneca
7.8.1 AstraZeneca Comapny Information
7.8.2 AstraZeneca Business Overview
7.8.3 AstraZeneca Adult and Pediatric Vaccines Revenue and Gross Margin (2020-2025)
7.8.4 AstraZeneca Adult and Pediatric Vaccines Product Portfolio
7.8.5 AstraZeneca Recent Developments
7.9 Takeda Pharmaceutical
7.9.1 Takeda Pharmaceutical Comapny Information
7.9.2 Takeda Pharmaceutical Business Overview
7.9.3 Takeda Pharmaceutical Adult and Pediatric Vaccines Revenue and Gross Margin (2020-2025)
7.9.4 Takeda Pharmaceutical Adult and Pediatric Vaccines Product Portfolio
7.9.5 Takeda Pharmaceutical Recent Developments
7.10 LG Life Sciences
7.10.1 LG Life Sciences Comapny Information
7.10.2 LG Life Sciences Business Overview
7.10.3 LG Life Sciences Adult and Pediatric Vaccines Revenue and Gross Margin (2020-2025)
7.10.4 LG Life Sciences Adult and Pediatric Vaccines Product Portfolio
7.10.5 LG Life Sciences Recent Developments
7.11 Bavarian Nordic
7.11.1 Bavarian Nordic Comapny Information
7.11.2 Bavarian Nordic Business Overview
7.11.3 Bavarian Nordic Adult and Pediatric Vaccines Revenue and Gross Margin (2020-2025)
7.11.4 Bavarian Nordic Adult and Pediatric Vaccines Product Portfolio
7.11.5 Bavarian Nordic Recent Developments
8 North America
8.1 North America Adult and Pediatric Vaccines Revenue (2020-2031)
8.2 North America Adult and Pediatric Vaccines Revenue by Type (2020-2031)
8.2.1 North America Adult and Pediatric Vaccines Revenue by Type (2020-2025)
8.2.2 North America Adult and Pediatric Vaccines Revenue by Type (2026-2031)
8.3 North America Adult and Pediatric Vaccines Revenue Share by Type (2020-2031)
8.4 North America Adult and Pediatric Vaccines Revenue by Application (2020-2031)
8.4.1 North America Adult and Pediatric Vaccines Revenue by Application (2020-2025)
8.4.2 North America Adult and Pediatric Vaccines Revenue by Application (2026-2031)
8.5 North America Adult and Pediatric Vaccines Revenue Share by Application (2020-2031)
8.6 North America Adult and Pediatric Vaccines Revenue by Country
8.6.1 North America Adult and Pediatric Vaccines Revenue by Country (2020 VS 2024 VS 2031)
8.6.2 North America Adult and Pediatric Vaccines Revenue by Country (2020-2025)
8.6.3 North America Adult and Pediatric Vaccines Revenue by Country (2026-2031)
8.6.4 United States
8.6.5 Canada
8.6.6 Mexico
9 Europe
9.1 Europe Adult and Pediatric Vaccines Revenue (2020-2031)
9.2 Europe Adult and Pediatric Vaccines Revenue by Type (2020-2031)
9.2.1 Europe Adult and Pediatric Vaccines Revenue by Type (2020-2025)
9.2.2 Europe Adult and Pediatric Vaccines Revenue by Type (2026-2031)
9.3 Europe Adult and Pediatric Vaccines Revenue Share by Type (2020-2031)
9.4 Europe Adult and Pediatric Vaccines Revenue by Application (2020-2031)
9.4.1 Europe Adult and Pediatric Vaccines Revenue by Application (2020-2025)
9.4.2 Europe Adult and Pediatric Vaccines Revenue by Application (2026-2031)
9.5 Europe Adult and Pediatric Vaccines Revenue Share by Application (2020-2031)
9.6 Europe Adult and Pediatric Vaccines Revenue by Country
9.6.1 Europe Adult and Pediatric Vaccines Revenue by Country (2020 VS 2024 VS 2031)
9.6.2 Europe Adult and Pediatric Vaccines Revenue by Country (2020-2025)
9.6.3 Europe Adult and Pediatric Vaccines Revenue by Country (2026-2031)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
9.6.9 Spain
9.6.10 Netherlands
9.6.11 Switzerland
9.6.12 Sweden
9.6.13 Poland
10 China
10.1 China Adult and Pediatric Vaccines Revenue (2020-2031)
10.2 China Adult and Pediatric Vaccines Revenue by Type (2020-2031)
10.2.1 China Adult and Pediatric Vaccines Revenue by Type (2020-2025)
10.2.2 China Adult and Pediatric Vaccines Revenue by Type (2026-2031)
10.3 China Adult and Pediatric Vaccines Revenue Share by Type (2020-2031)
10.4 China Adult and Pediatric Vaccines Revenue by Application (2020-2031)
10.4.1 China Adult and Pediatric Vaccines Revenue by Application (2020-2025)
10.4.2 China Adult and Pediatric Vaccines Revenue by Application (2026-2031)
10.5 China Adult and Pediatric Vaccines Revenue Share by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Adult and Pediatric Vaccines Revenue (2020-2031)
11.2 Asia Adult and Pediatric Vaccines Revenue by Type (2020-2031)
11.2.1 Asia Adult and Pediatric Vaccines Revenue by Type (2020-2025)
11.2.2 Asia Adult and Pediatric Vaccines Revenue by Type (2026-2031)
11.3 Asia Adult and Pediatric Vaccines Revenue Share by Type (2020-2031)
11.4 Asia Adult and Pediatric Vaccines Revenue by Application (2020-2031)
11.4.1 Asia Adult and Pediatric Vaccines Revenue by Application (2020-2025)
11.4.2 Asia Adult and Pediatric Vaccines Revenue by Application (2026-2031)
11.5 Asia Adult and Pediatric Vaccines Revenue Share by Application (2020-2031)
11.6 Asia Adult and Pediatric Vaccines Revenue by Country
11.6.1 Asia Adult and Pediatric Vaccines Revenue by Country (2020 VS 2024 VS 2031)
11.6.2 Asia Adult and Pediatric Vaccines Revenue by Country (2020-2025)
11.6.3 Asia Adult and Pediatric Vaccines Revenue by Country (2026-2031)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 Taiwan
11.6.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Adult and Pediatric Vaccines Revenue (2020-2031)
12.2 SAMEA Adult and Pediatric Vaccines Revenue by Type (2020-2031)
12.2.1 SAMEA Adult and Pediatric Vaccines Revenue by Type (2020-2025)
12.2.2 SAMEA Adult and Pediatric Vaccines Revenue by Type (2026-2031)
12.3 SAMEA Adult and Pediatric Vaccines Revenue Share by Type (2020-2031)
12.4 SAMEA Adult and Pediatric Vaccines Revenue by Application (2020-2031)
12.4.1 SAMEA Adult and Pediatric Vaccines Revenue by Application (2020-2025)
12.4.2 SAMEA Adult and Pediatric Vaccines Revenue by Application (2026-2031)
12.5 SAMEA Adult and Pediatric Vaccines Revenue Share by Application (2020-2031)
12.6 SAMEA Adult and Pediatric Vaccines Revenue by Country
12.6.1 SAMEA Adult and Pediatric Vaccines Revenue by Country (2020 VS 2024 VS 2031)
12.6.2 SAMEA Adult and Pediatric Vaccines Revenue by Country (2020-2025)
12.6.3 SAMEA Adult and Pediatric Vaccines Revenue by Country (2026-2031)
12.6.4 Brazil
12.6.5 Argentina
12.6.6 Chile
12.6.7 Colombia
12.6.8 Peru
12.6.9 Saudi Arabia
12.6.10 Israel
12.6.11 UAE
12.6.12 Turkey
12.6.13 Iran
12.6.14 Egypt
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.